Please login to the form below

Patient Compliance – Cracking that Big Nut!

In this month’s column we look at the issue of non-adherence, the risk of bias in adherence surveys and how a better understanding of true patient behavior is critical to improving compliance.
Consider the scenario – the physician has been detailed, is sold on your brand and prescribes it to the patient. Unfortunately, the patient, perhaps unconvinced of the drug’s benefits, either doesn’t fill the prescription or fails to properly adhere to the treatment regime – that’s assuming they even present in the first place. The consequence for many patients is that they don’t get the best outcomes and end up with negative perceptions of the drug. The consequence for pharma, of course, is that drug sales are impacted and brand image is damaged.

Non-adherence is a very common problem and a big issue for pharma, especially in chronic disease areas like diabetes, hypertension and osteoporosis. The pharmaceutical industry has invested significant time and money trying to solve this issue, particularly with the use of memory aids ranging from simple pill boxes to sophisticated wireless devices. But how effective are these aids?   We recently undertook a study[i] to investigate compliance in type 2 diabetes. We were looking to address a common dilemma market researchers face – which is that compliance is actually quite difficult to measure. Traditional methods, such as diary studies, can give results where respondents are found to overstate how compliant they really are. Patients may say or recall taking their medication when they did not. The simple act of asking them to complete a diary can introduce bias into the process – the respondent becomes more compliant because the survey is reminding them to be! Electronic monitoring systems which can tell when a patient takes their medication are the gold standard but these systems don’t explain why patients do or don’t comply with their treatment program.

So we thought we would try using a research approach which would engage patients, not act as a reminder, could be self-administered and easy to manage. Research using mobile phones was ideal because we could recruit respondents and survey them at random times over a period, at key moments when they were following their regular routine.  We wanted to see if this approach would elicit greater insights into compliant and non-compliant behavior. 

A major finding of the study was that we did find that patients are not as compliant as they think they are. Whilst 82% said they were compliant, only 62% were really taking their medication as prescribed. We found that compliance aids, such as pill boxes, gave patients a false sense of reassurance – 90% of those who had a compliance aid perceived themselves to be compliant, when 54% of these actually were. Those who didn’t have a compliance aid perceived themselves to be less compliant – 75% - but actually 74% of these patients were found to be compliant.

The pharma industry needs to look at compliance aids and at the advice surrounding these tools to see if they can educate patients to use them more effectively.  

We found certain circumstances related to compliant behavior. Unsurprisingly, we found that patients who comply are much more satisfied with their medication than those who aren’t. The more support patients are given from HCPs, friends and family, the more compliant the recorded behavior. And if they said they had a ‘good relationship’ with their PCP, then they were more likely to be compliant. We also found that routine has a large impact on compliance behavior. Eighty percent of patients who did have a routine were compliant, compared with 40% compliance from those who didn’t.

The implication for pharma is that compliance remains an issue which needs to be addressed, but it isn’t enough to give patients compliance tools and think that this is going to change behavior. And it isn’t enough to rely on anecdotal evidence because when a nurse educator hears a patient say ‘’I use a days of the week pill box to help me to remember to take my medications’ or ‘I’m really organized, I put them all in a box”, it may not be confirmation that a patient is being compliant. Understanding how a patient really integrates their medications into their daily routine and what factors really affect compliance, are critical to influencing and changing patient behavior.

Published 
Jun 11, 2013 eyeforpharma.com

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more at http://bit.ly/1cigMnO

22nd November 2013

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Rare diseases and orphan drugs: Our experience and expertise

Research Partnership
Conducting research for publication video

Research Partnership
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Research Partnership
Portfolio analysis: Using market research to master communications across a therapeutic category

Research Partnership
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Research Partnership
Patients’willingness to pay
Considerations when developing an appropriate pricing strategy in self-pay markets
Research Partnership